Key Points
- Roivant Sciences director Melissa Epperly sold 4,938 shares at an average price of $39.74, generating $196,236.12. The Rule 10b5-1 transaction reduced her holdings by 33.28% to 9,900 shares.
- ROIV shares opened at $39.98 and have traded between $14.50 and $42.50 over the past year. The company recently beat quarterly EPS expectations, reporting a loss of $0.26 per share versus the consensus loss of $0.30, though revenue fell short of estimates.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $45.64. Institutional investors own 64.76% of the company, while several firms recently increased their stakes.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Melissa Epperly sold 4,938 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $39.74, for a total value of $196,236.12. Following the transaction, the director owned 9,900 shares in the company, valued at approximately $393,426. This trade represents a 33.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Roivant Sciences Trading Up 1.0%
NASDAQ:ROIV opened at $39.98 on Friday. The stock has a 50 day simple moving average of $36.10 and a 200 day simple moving average of $31.97. The stock has a market cap of $28.88 billion, a P/E ratio of -75.43 and a beta of 1.12. Roivant Sciences Ltd. has a 1-year low of $14.50 and a 1-year high of $42.50.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, sell-side analysts forecast that Roivant Sciences Ltd. will post -2 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC raised its holdings in shares of Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock worth $57,000 after buying an additional 520 shares in the last quarter. Bessemer Group Inc. grew its position in Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock valued at $69,000 after acquiring an additional 441 shares during the last quarter. Allworth Financial LP grew its position in Roivant Sciences by 42.1% in the fourth quarter. Allworth Financial LP now owns 2,551 shares of the company's stock valued at $55,000 after acquiring an additional 756 shares during the last quarter. Clearstead Advisors LLC raised its stake in Roivant Sciences by 141.6% during the fourth quarter. Clearstead Advisors LLC now owns 2,907 shares of the company's stock worth $63,000 after acquiring an additional 1,704 shares in the last quarter. Finally, Root Financial Partners LLC lifted its holdings in shares of Roivant Sciences by 187.9% in the first quarter. Root Financial Partners LLC now owns 2,914 shares of the company's stock worth $81,000 after acquiring an additional 1,902 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities analysts recently commented on ROIV shares. Piper Sandler reaffirmed an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Sanford C. Bernstein upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Wednesday, July 29th. HC Wainwright boosted their price target on Roivant Sciences from $41.00 to $47.00 and gave the company a "buy" rating in a research note on Tuesday, September 8th. Citigroup increased their price target on Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Roivant Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.64.
Get Our Latest Stock Analysis on Roivant Sciences
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.
Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
